医学
安慰剂
不利影响
随机对照试验
内科学
PCSK9
胃肠病学
胆固醇
脂蛋白
低密度脂蛋白受体
替代医学
病理
作者
Christie M. Ballantyne,Puja Banka,Gustavo Méndez,Raymundo Garcia,Julio Rosenstock,Anthony Rodgers,Geraldine Mendizabal,Yale Mitchel,Alberico L. Catapano
标识
DOI：10.1016/j.jacc.2023.02.018
摘要
MK-0616 demonstrated statistically significant and robust, dose-dependent placebo-adjusted reductions in LDL-C at Week 8 of up to 60.9% from baseline and was well tolerated during 8 weeks of treatment and an additional 8 weeks of follow-up. (A Study of the Efficacy and Safety of MK-0616 [Oral PCSK9 Inhibitor] in Adults With Hypercholesterolemia [MK-0616-008]; NCT05261126).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
Ethan
郭竞阳
AllRightReserved
愔愔
嘻嘻哈哈
贪玩的秋柔
Criminology34
OsamaKareem
arbitmomo
YifanWang
无极微光
Tong
Moonpie
fearless
小宋
嘉心糖
Hayat
Nexus
ZeKaWa
皖公网安备34019202002308
